NASDAQ · ATTO
Attovia Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ATTO: Dec 2, 2026
Attovia Therapeutics, Inc. Common Stock is estimated to report earnings on 12/02/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.74.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Dec 2026 | $-0.53 | $-0.53 | $-0.53 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · Fintel · RTTNews- BNK Invest · Oct 23, 4:35 PM EDTAttovia Therapeutics Becomes Oversold (ATTO)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- Fintel · Sep 17, 6:33 AM EDTAttovia Therapeutics Consensus Price Target Increased by 344.21% to $43.04The average one-year price target for Attovia Therapeutics (NASDAQGM:ATTO) has been revised to $43.04 / share, as of September 11, 2026. This is an increase of 344.21% from the prior estimate of $9.69 dated July 5, 2023. These figures represent aggregate analyst targets compiled
- RTTNews · Sep 4, 2:36 PM EDT5 Biotech And Medical Device Stocks In Focus: Pro-Dex, Modular Medical, ENvue Medical & More(RTTNews) – Several biotech and medical device stocks were in focus Friday, including Pro-Dex following strong fiscal 2026 results; Modular Medical after FDA clearance for Pivot patch pump software enhancements; and ENvue Medical following its selection for the Vizient Innovative
- RTTNews · Sep 4, 5:15 AM EDTBiotech Stocks At 52-Week Highs – ATTO, HALO, IKT, TVTX, ATRC(RTTNews) – The following biotech stocks reached a 52-week high on September 3, 2026, as various clinical trials reported financial results and reached certain regulatory milestones.
- RTTNews · Sep 3, 12:47 PM EDTAttovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27(RTTNews) – Attovia Therapeutics Inc. (ATTO), a clinical stage biopharmaceutical company, on Wednesday reported a wider net loss in financial results for the second quarter, owing to increased clinical, preclinical, and manufacturing costs.
- Fintel · Sep 1, 7:24 PM EDTMorgan Stanley Initiates Coverage of Attovia Therapeutics (ATTO) with Overweight RecommendationFintel reports that on August 31, 2026, Morgan Stanley initiated coverage of Attovia Therapeutics (NASDAQGM:ATTO) with a Overweight recommendation. Analyst Price Forecast Suggests 54.72% Downside
- Fintel · Sep 1, 7:23 PM EDTRBC Capital Initiates Coverage of Attovia Therapeutics (ATTO) with Outperform RecommendationFintel reports that on August 31, 2026, RBC Capital initiated coverage of Attovia Therapeutics (NASDAQGM:ATTO) with a Outperform recommendation. Analyst Price Forecast Suggests 54.72% Downside
- Fintel · Sep 1, 7:23 PM EDTLeerink Partners Initiates Coverage of Attovia Therapeutics (ATTO) with Outperform RecommendationFintel reports that on August 31, 2026, Leerink Partners initiated coverage of Attovia Therapeutics (NASDAQGM:ATTO) with a Outperform recommendation. Analyst Price Forecast Suggests 54.72% Downside
- Fintel · Sep 1, 7:23 PM EDTLifeSci Capital Initiates Coverage of Attovia Therapeutics (ATTO) with Outperform RecommendationFintel reports that on August 31, 2026, LifeSci Capital initiated coverage of Attovia Therapeutics (NASDAQGM:ATTO) with a Outperform recommendation. Analyst Price Forecast Suggests 54.72% Downside
- Fintel · Sep 1, 7:23 PM EDTCitigroup Initiates Coverage of Attovia Therapeutics (ATTO) with Buy RecommendationFintel reports that on August 31, 2026, Citigroup initiated coverage of Attovia Therapeutics (NASDAQGM:ATTO) with a Buy recommendation. Analyst Price Forecast Suggests 54.72% Downside
- BNK Invest · Aug 10, 10:59 AM EDTMonday 8/10 Insider Buying Report: ATTO, BWFGAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at one noteworthy recent insider buy. And at Bankwell Financial Group, there was insider buying on Friday, by Director Law
- RTTNews · Aug 5, 11:38 PM EDTTop Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High(RTTNews) – Today's top biotech gainers include Attovia Therapeutics, which surged following its Nasdaq debut; American Well, after reporting a narrower loss; Perrigo, which swung back to profit; and UroGen Pharma, following strong second-quarter financial results, among others.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Attovia Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.